Description: Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz, Gelclair, Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.
Home Page: www.midatechpharma.com
MTPH Technical Analysis
1 Caspian Point
Cardiff,
CF10 4DQ
United Kingdom
Phone:
44 29 2048 0180
Officers
| Name | Title |
|---|---|
| Mr. Stephen A. Stamp | CEO, CFO, Company Sec. & Director |
| Dr. Dmitry Zamoryakhin M.D. | Chief Scientific Officer |
| Dr. Daniel Palmer MBA, Ph.D. | VP of Technology |
| Dr. Tim Sparey Ph.D. | Chief Bus. Officer |
| Mr. Justin Barry BSc (Hons.), MBIOL, CBIOL, QP | Head of Manufacturing |
| Mr. Vincent Holmes | VP & Head of Clinical Operations |
| Mr. David Benharris | Pres of Midatech Pharma US Inc |
| Ms. Fiona Sharp | Group Financial Controller |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7494 |
| Price-to-Sales TTM: | 7.4606 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 20 |